title: Two lyophilized polymer matrix recombinant human bone morphogenetic protein-2 carriers in rabbit calvarial defects.
abstract: We have developed a lyophilized bone morphogenetic protein (BMP) delivery device that can be formulated to control release over 2 to 8 weeks. Bioerodible poly (d,l lactide-co-glycolide) particles loaded with 90 micrograms recombinant human BMP-2 were suspended in either carboxymethylcellulose (CMC) or methylcellulose (MC) implants. Plain CMC and MC implants served as controls, as did a nonimplanted group. A total of 40 rabbits was evaluated histologically 2, 4, or 8 weeks after receiving circular full-thickness 15-mm calvarial defects. MC appeared to prevent prolapse of periosteum and dura into the defects and did not elicit bone growth. Addition of BMP improved the result. CMC implants appeared to encourage bone growth even in the absence of BMP. When BMP was added, new bone formed earlier. CMC may influence new bone formation because it is hydrophilic. MC is less hydrophilic and may cause undue inflammation. Either can be combined with BMP to produce unitary devices that are easy to make and use.
authors.affiliation: Department of Surgery, University of Kentucky, Lexington 40536-0284, USA.
authors.forename: J B
authors.initials: JB
authors.lastname: Rodgers
authors.forename: H C
authors.initials: HC
authors.lastname: Vasconez
authors.forename: M D
authors.initials: MD
authors.lastname: Wells
authors.forename: P P
authors.initials: PP
authors.lastname: DeLuca
authors.forename: M C
authors.initials: MC
authors.lastname: Faugere
authors.forename: B F
authors.initials: BF
authors.lastname: Fink
authors.forename: D
authors.initials: D
authors.lastname: Hamilton
mesh_terms: D000818:Animals; D001672:Biocompatible Materials; D001846:Bone Development / Q000187:drug effects; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000494:pharmacology; D002266:Carboxymethylcellulose Sodium; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D004343:Drug Implants; D005612:Freeze Drying; D006801:Humans; D019344:Lactic Acid; D008297:Male; D008747:Methylcellulose; D010592:Pharmaceutic Aids; D010865:Pilot Projects; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012886:Skull / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D016212:Transforming Growth Factor beta
chemical_list: C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D003692:Delayed-Action Preparations; D004343:Drug Implants; D010592:Pharmaceutic Aids; D011108:Polymers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D008747:Methylcellulose; D002266:Carboxymethylcellulose Sodium